Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 678 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mild Alzheimer's Disease Clear all
Terminated Phase 4 Interventional

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

NCT00369603
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Razadyne ER, Aricept
Drug
Lead sponsor
Duke University
Other
Eligibility
40 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 2 Interventional

Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease

NCT00244322
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY450139 dihydrate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2007 · Synced Sep 30, 2026, 3:46 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Core Center

NCT01421420
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Memory Disorders
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
50 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Sep 30, 2026, 3:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)

NCT06597942
View directory record Official record
Conditions
Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease, Moderate Alzheimer&Amp;Amp;#39;s Disease, Alzheimer&Amp;#39;s Disease (AD), Alzheimer&Amp;#39;s Dementia
Interventions
TMS, Transcranial Magnetic Stimulation Sham
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years to 100 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 3 Interventional Results available

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

NCT02006654
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
26
States / cities
Mesa, Arizona • Bellflower, California • Costa Mesa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 30, 2026, 3:46 AM EDT
Withdrawn Phase 2 Interventional

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

NCT02246075
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
2
States / cities
Delray Beach, Florida • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

NCT00483028
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
donezepil (Aricept)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Haven, Connecticut • Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2008 · Synced Sep 30, 2026, 3:46 AM EDT
Terminated Phase 3 Interventional Results available

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

NCT01900665
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 90 Years
Enrollment
2,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
120
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 30, 2026, 3:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Measures of CSF Clearance in Preclinical Alzheimer's Disease

NCT03663387
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 30, 2026, 3:46 AM EDT
Active, not recruiting Early Phase 1 Interventional

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

NCT04075435
View directory record Official record
Conditions
Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
high CBD/low THC sublingual solution
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 2 Interventional

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SRA-333
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Sep 30, 2026, 3:46 AM EDT
Terminated Not applicable Interventional Results available

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

NCT01082965
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 30, 2026, 3:46 AM EDT
Completed No phase listed Observational

Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment

NCT03912571
View directory record Official record
Conditions
Sleep Disorder
Interventions
Structural 3T MRI, MRI Based Perfusion Imaging, VR-CO2 MRI Scans
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Sep 30, 2026, 3:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurotrack Test Validation Protocol

NCT02608021
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Sep 30, 2026, 3:46 AM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate Coconut Oil for Alzheimer's Disease

NCT01883648
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Coconut Oil Beverage, Placebo Beverage
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
55 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 2 Interventional Results available

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

NCT00722046
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365 0.1 mg/kg, PF-04360365 0.5 mg/kg, PF-04360365 1 mg/kg, Placebo, PF-04360365 3 mg/kg, PF-04360365 8.5 mg/kg
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Peoria, Arizona • Phoenix, Arizona • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 30, 2026, 3:46 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

NCT05834296
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ALZN002 (autologous DCs pulsed with E22W mutant peptide)., Placebo
Biological · Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

NCT03522129
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

NCT01343966
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MABT5102A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
40
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 30, 2026, 3:46 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

NCT06254469
View directory record Official record
Conditions
Alzheimer Disease, Chronic Traumatic Encephalopathy
Interventions
[F-18]Flornaptitril
Drug
Lead sponsor
CereMark Pharma, LLC
Industry
Eligibility
45 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 1 Interventional

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

NCT03008161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NPT088, Placebo
Drug
Lead sponsor
Proclara Biosciences, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Costa Mesa, California • Fullerton, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 30, 2026, 3:46 AM EDT
Not listed No phase listed Observational

Diagnosis of Alzheimer's Disease Using Event Related Potentials

NCT02957227
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
No intervention is part of this study but patients use an EEG device during observational data collection.
Device
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
50 Years to 100 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Sep 30, 2026, 3:46 AM EDT
Completed Phase 2 Interventional

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tricaprilin, Placebo
Drug · Other
Lead sponsor
Cerecin
Industry
Eligibility
50 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 30, 2026, 3:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease

NCT07659964
View directory record Official record
Conditions
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Interventions
Metronome
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 30, 2026, 3:46 AM EDT